Australasian Lung Cancer Trials Group   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Milton Australia (2004)

Organization Overview

First Clinical Trial
2014
NCT02273375
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Australasian Lung Cancer Trials Group

Active Ingredients

Drugs in Phase 3 Trials (1)

durvalumab (imfinzi) (2 trials)

Drugs in Phase 2 Trials (1)

tremelimumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Mesothelioma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2